{
  "success": true,
  "pagesUsed": [
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46
  ],
  "modelUsed": "gemini-3-flash-preview",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Age requirement",
        "text": "≥ 18 years of age.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Disease status",
        "text": "Histologically or cytologically confirmed breast cancer that is either locally advanced or metastatic. Locally advanced breast cancer must not be primarily amenable to surgical resection or radiation with curative intent. Patients with bone-only disease and/or hormone receptor positive disease should be deemed by the investigator as appropriate candidates for combination chemotherapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "BRCA mutation",
        "text": "Suspected deleterious or deleterious BRCA1 or BRCA2 germline mutation. The investigator should ensure that the testing is consistent with local guidelines, and clinical practice, and that the test uses either 1) direct DNA sequencing/multiplex ligation-dependent probe amplification (MLPA) or 2) a well-characterized methodology previously validated by sequencing, such as that used to assess founder mutations. If testing has been performed prior to Study M12-914, subjects may be enrolled but must be re-tested by the Sponsor core laboratory for documentation of BRCA1 or BRCA2 germline mutations. Subjects with BRCA variants of uncertain significance or polymorphisms in BRCA1 or BRCA2 will not be eligible for the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "HER2 status",
        "text": "Breast cancer must be HER2-negative defined as IHC 0 – 1+ OR HER2-neu negative according to ASCO-CAP41 guideline recommendations (Appendix K).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Measurable disease",
        "text": "Measurable or non-measurable (but radiologically evaluable) disease per RECIST (version 1.1) on CT scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Performance status",
        "text": "ECOG performance status of 0 to 2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Oral medication tolerance",
        "text": "Subject is able to swallow and retain oral medication and does not have uncontrolled emesis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Organ function",
        "text": "Adequate hematologic, renal, and hepatic function as follows (within 28 days of randomization): Bone Marrow: Absolute neutrophil count (ANC) ≥ 1500/mm3 (1.5 × 109/L); Platelets ≥ 100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.5 g/dL (5.89 mmol/L); Renal Function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) range OR creatinine clearance ≥ 50 mL/min/1.73 m2 (according to local assessment method) for subjects with creatinine levels above institutional normal; Hepatic Function: AST ≤ 2.5 × upper limit of normal; ALT ≤ 2.5 × upper limit of normal, bilirubin ≤ 1.5 × the ULN range. For subjects with liver metastases, AST < 5 × ULN range; ALT < 5 × ULN range. Subjects with Gilbert's syndrome may have a bilirubin ≥ 1.5 × the ULN range, if no evidence of biliary obstruction exists; Activated Partial Thromboplastin Time (APTT) must be ≤ 1.5 × the ULN range and INR < 1.5. Subjects on anticoagulant therapy will have an appropriate APTT and INR as determined by the investigator.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Contraception",
        "text": "Women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation, and for 6 months following completion of therapy. If male, subjects and subject's female partner(s) of childbearing potential should practice at least one of the following methods of birth control. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to randomization (within 24 hours). To be considered of non-childbearing potential, postmenopausal women must be amenorrheic for at least 12 months or subjects must be surgically sterile. Total abstinence from sexual intercourse; Vasectomized male subjects or vasectomized partner of female subjects; Double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or cream); or Intra-Uterine Device (IUD). Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms and refrain from sperm donation for the duration of the study and for 6 months following completion of therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Informed consent",
        "text": "Capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by an IEC/IRB, prior to initiation of any screening or study-specific procedures.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Prior therapy timing",
        "text": "Received anticancer agent(s) or an investigational agent within 21 days prior to C1D-2 or radiotherapy within 28 days prior to C1D-2. Prior treatment with palliative local breast or bone lesion radiation (other than pelvis) can occur, if administered at least 14 days prior to C1D-2. Anticancer hormonal therapy must be stopped 7 days before starting C1D-2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Prior chemotherapy lines",
        "text": "Received more than 2 prior lines of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease. Regimens received in the adjuvant/neoadjuvant setting or for locally advanced breast cancer within the past 6 months will also be considered toward the maximum of 2 prior lines of therapy. Adjuvant/neoadjuvant chemotherapy for one cancer event will count as one prior line of therapy, if received within the past 6 months.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Prior platinum therapy",
        "text": "Progressed or recurred within 12 months of completing platinum therapy or received > 1 prior line of platinum therapy for breast cancer in any setting (adjuvant, neoadjuvant or metastatic).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Unrecovered toxicity",
        "text": "Subjects experiencing a significant adverse effect or toxicity (Grade 3 or Grade 4), causally attributed to previous anticancer treatment that has not recovered to at least Grade 2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Prior PARP inhibitors",
        "text": "Prior therapy with PARP inhibitors.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Prior taxane therapy",
        "text": "Prior taxane therapy administered for the treatment of metastatic breast cancer with the below exceptions: Prior taxane therapy for metastatic breast cancer is allowed if the patient received ≤ 1 full cycle in the absence of progression or if taxane therapy for metastatic disease was > 12 months prior to C1D-2. Use of taxanes as adjuvant therapy or to treat locally advanced disease is permitted, if given more than 6 months prior to C1D-2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Brain metastases",
        "text": "Subjects with active brain metastases or leptomeningeal disease. Subjects with known brain metastases must have clinically controlled neurologic symptoms and have received previous adequate treatment, defined as surgical excision and/or radiation therapy with stable neurologic function and no evidence of Central Nervous System (CNS) disease progression as determined by comparing a CT scan or MRI scan performed during screening to a prior scan performed at least 4 weeks earlier and provided that the subject is asymptomatic, has no evidence of cavitation or hemorrhage, and does not require corticosteroids.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Seizure disorder",
        "text": "A history of uncontrolled seizure disorder, including focal or generalized seizure within the past year.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Neuropathy",
        "text": "Pre-existing neuropathy from any cause in excess of Grade 1 (except focal neuropathy such as brachial plexopathy or carpal tunnel syndrome).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Major surgery",
        "text": "Major surgery within 3 weeks of randomization.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Allergic reactions",
        "text": "Known history of allergic reaction to cremophor/paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drugs.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Uncontrolled conditions",
        "text": "Clinically significant uncontrolled condition(s) including, but not limited to: Active infection; Symptomatic congestive heart failure; Unstable angina pectoris or cardiac arrhythmia; Myocardial infarction within last 6 months; Known active hepatitis B or hepatitis C with abnormal liver function tests or organ dysfunction; Uncontrolled hypertension; Psychiatric illness/social situations that would limit compliance; Any medical condition that, in the opinion of the investigator, places the subject at an unacceptably high risk.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Other cancers",
        "text": "A previous or concurrent cancer that is distinct in primary site or histology from breast cancer, except cervical carcinoma in situ, non-melanoma carcinoma of the skin, or in situ carcinoma of the bladder or another in situ cancer that is considered cured by the Investigator. Any cancer curatively treated more than 3 years prior to entry is permitted.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Pregnancy/Breastfeeding",
        "text": "Pregnant or breastfeeding.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Age requirement",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "Disease status",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "BRCA mutation",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "HER2 status",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "Measurable disease",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "Performance status",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "Oral medication tolerance",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "Organ function",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception",
        "previousId": "ec_8",
        "nextId": "ec_10"
      },
      {
        "id": "ec_10",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion",
        "name": "Informed consent",
        "previousId": "ec_9"
      },
      {
        "id": "ec_11",
        "identifier": "E1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion",
        "name": "Prior therapy timing",
        "nextId": "ec_12"
      },
      {
        "id": "ec_12",
        "identifier": "E2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion",
        "name": "Prior chemotherapy lines",
        "previousId": "ec_11",
        "nextId": "ec_13"
      },
      {
        "id": "ec_13",
        "identifier": "E3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion",
        "name": "Prior platinum therapy",
        "previousId": "ec_12",
        "nextId": "ec_14"
      },
      {
        "id": "ec_14",
        "identifier": "E4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion",
        "name": "Unrecovered toxicity",
        "previousId": "ec_13",
        "nextId": "ec_15"
      },
      {
        "id": "ec_15",
        "identifier": "E5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion",
        "name": "Prior PARP inhibitors",
        "previousId": "ec_14",
        "nextId": "ec_16"
      },
      {
        "id": "ec_16",
        "identifier": "E6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion",
        "name": "Prior taxane therapy",
        "previousId": "ec_15",
        "nextId": "ec_17"
      },
      {
        "id": "ec_17",
        "identifier": "E7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion",
        "name": "Brain metastases",
        "previousId": "ec_16",
        "nextId": "ec_18"
      },
      {
        "id": "ec_18",
        "identifier": "E8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion",
        "name": "Seizure disorder",
        "previousId": "ec_17",
        "nextId": "ec_19"
      },
      {
        "id": "ec_19",
        "identifier": "E9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion",
        "name": "Neuropathy",
        "previousId": "ec_18",
        "nextId": "ec_20"
      },
      {
        "id": "ec_20",
        "identifier": "E10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion",
        "name": "Major surgery",
        "previousId": "ec_19",
        "nextId": "ec_21"
      },
      {
        "id": "ec_21",
        "identifier": "E11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion",
        "name": "Allergic reactions",
        "previousId": "ec_20",
        "nextId": "ec_22"
      },
      {
        "id": "ec_22",
        "identifier": "E12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion",
        "name": "Uncontrolled conditions",
        "previousId": "ec_21",
        "nextId": "ec_23"
      },
      {
        "id": "ec_23",
        "identifier": "E13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion",
        "name": "Other cancers",
        "previousId": "ec_22",
        "nextId": "ec_24"
      },
      {
        "id": "ec_24",
        "identifier": "E14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion",
        "name": "Pregnancy/Breastfeeding",
        "previousId": "ec_23"
      }
    ],
    "summary": {
      "inclusionCount": 10,
      "exclusionCount": 14,
      "totalCount": 24
    },
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24"
      ],
      "instanceType": "StudyDesignPopulation",
      "description": "Target population defined by eligibility criteria"
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Age requirement",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "Disease status",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "BRCA mutation",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "HER2 status",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "Measurable disease",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "Performance status",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "Oral medication tolerance",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "Organ function",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Contraception",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_10",
        "name": "Informed consent",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_11",
        "name": "Prior therapy timing",
        "identifier": "E1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_12",
        "name": "Prior chemotherapy lines",
        "identifier": "E2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_13",
        "name": "Prior platinum therapy",
        "identifier": "E3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_14",
        "name": "Unrecovered toxicity",
        "identifier": "E4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_15",
        "name": "Prior PARP inhibitors",
        "identifier": "E5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_16",
        "name": "Prior taxane therapy",
        "identifier": "E6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_17",
        "name": "Brain metastases",
        "identifier": "E7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_18",
        "name": "Seizure disorder",
        "identifier": "E8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_19",
        "name": "Neuropathy",
        "identifier": "E9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_20",
        "name": "Major surgery",
        "identifier": "E10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_21",
        "name": "Allergic reactions",
        "identifier": "E11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_22",
        "name": "Uncontrolled conditions",
        "identifier": "E12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_23",
        "name": "Other cancers",
        "identifier": "E13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_24",
        "name": "Pregnancy/Breastfeeding",
        "identifier": "E14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Age requirement",
        "text": "≥ 18 years of age.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Disease status",
        "text": "Histologically or cytologically confirmed breast cancer that is either locally advanced or metastatic. Locally advanced breast cancer must not be primarily amenable to surgical resection or radiation with curative intent. Patients with bone-only disease and/or hormone receptor positive disease should be deemed by the investigator as appropriate candidates for combination chemotherapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "BRCA mutation",
        "text": "Suspected deleterious or deleterious BRCA1 or BRCA2 germline mutation. The investigator should ensure that the testing is consistent with local guidelines, and clinical practice, and that the test uses either 1) direct DNA sequencing/multiplex ligation-dependent probe amplification (MLPA) or 2) a well-characterized methodology previously validated by sequencing, such as that used to assess founder mutations. If testing has been performed prior to Study M12-914, subjects may be enrolled but must be re-tested by the Sponsor core laboratory for documentation of BRCA1 or BRCA2 germline mutations. Subjects with BRCA variants of uncertain significance or polymorphisms in BRCA1 or BRCA2 will not be eligible for the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "HER2 status",
        "text": "Breast cancer must be HER2-negative defined as IHC 0 – 1+ OR HER2-neu negative according to ASCO-CAP41 guideline recommendations (Appendix K).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Measurable disease",
        "text": "Measurable or non-measurable (but radiologically evaluable) disease per RECIST (version 1.1) on CT scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Performance status",
        "text": "ECOG performance status of 0 to 2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Oral medication tolerance",
        "text": "Subject is able to swallow and retain oral medication and does not have uncontrolled emesis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Organ function",
        "text": "Adequate hematologic, renal, and hepatic function as follows (within 28 days of randomization): Bone Marrow: Absolute neutrophil count (ANC) ≥ 1500/mm3 (1.5 × 109/L); Platelets ≥ 100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.5 g/dL (5.89 mmol/L); Renal Function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) range OR creatinine clearance ≥ 50 mL/min/1.73 m2 (according to local assessment method) for subjects with creatinine levels above institutional normal; Hepatic Function: AST ≤ 2.5 × upper limit of normal; ALT ≤ 2.5 × upper limit of normal, bilirubin ≤ 1.5 × the ULN range. For subjects with liver metastases, AST < 5 × ULN range; ALT < 5 × ULN range. Subjects with Gilbert's syndrome may have a bilirubin ≥ 1.5 × the ULN range, if no evidence of biliary obstruction exists; Activated Partial Thromboplastin Time (APTT) must be ≤ 1.5 × the ULN range and INR < 1.5. Subjects on anticoagulant therapy will have an appropriate APTT and INR as determined by the investigator.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Contraception",
        "text": "Women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation, and for 6 months following completion of therapy. If male, subjects and subject's female partner(s) of childbearing potential should practice at least one of the following methods of birth control. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to randomization (within 24 hours). To be considered of non-childbearing potential, postmenopausal women must be amenorrheic for at least 12 months or subjects must be surgically sterile. Total abstinence from sexual intercourse; Vasectomized male subjects or vasectomized partner of female subjects; Double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or cream); or Intra-Uterine Device (IUD). Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms and refrain from sperm donation for the duration of the study and for 6 months following completion of therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Informed consent",
        "text": "Capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by an IEC/IRB, prior to initiation of any screening or study-specific procedures.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Prior therapy timing",
        "text": "Received anticancer agent(s) or an investigational agent within 21 days prior to C1D-2 or radiotherapy within 28 days prior to C1D-2. Prior treatment with palliative local breast or bone lesion radiation (other than pelvis) can occur, if administered at least 14 days prior to C1D-2. Anticancer hormonal therapy must be stopped 7 days before starting C1D-2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Prior chemotherapy lines",
        "text": "Received more than 2 prior lines of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease. Regimens received in the adjuvant/neoadjuvant setting or for locally advanced breast cancer within the past 6 months will also be considered toward the maximum of 2 prior lines of therapy. Adjuvant/neoadjuvant chemotherapy for one cancer event will count as one prior line of therapy, if received within the past 6 months.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Prior platinum therapy",
        "text": "Progressed or recurred within 12 months of completing platinum therapy or received > 1 prior line of platinum therapy for breast cancer in any setting (adjuvant, neoadjuvant or metastatic).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Unrecovered toxicity",
        "text": "Subjects experiencing a significant adverse effect or toxicity (Grade 3 or Grade 4), causally attributed to previous anticancer treatment that has not recovered to at least Grade 2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Prior PARP inhibitors",
        "text": "Prior therapy with PARP inhibitors.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Prior taxane therapy",
        "text": "Prior taxane therapy administered for the treatment of metastatic breast cancer with the below exceptions: Prior taxane therapy for metastatic breast cancer is allowed if the patient received ≤ 1 full cycle in the absence of progression or if taxane therapy for metastatic disease was > 12 months prior to C1D-2. Use of taxanes as adjuvant therapy or to treat locally advanced disease is permitted, if given more than 6 months prior to C1D-2.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Brain metastases",
        "text": "Subjects with active brain metastases or leptomeningeal disease. Subjects with known brain metastases must have clinically controlled neurologic symptoms and have received previous adequate treatment, defined as surgical excision and/or radiation therapy with stable neurologic function and no evidence of Central Nervous System (CNS) disease progression as determined by comparing a CT scan or MRI scan performed during screening to a prior scan performed at least 4 weeks earlier and provided that the subject is asymptomatic, has no evidence of cavitation or hemorrhage, and does not require corticosteroids.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Seizure disorder",
        "text": "A history of uncontrolled seizure disorder, including focal or generalized seizure within the past year.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Neuropathy",
        "text": "Pre-existing neuropathy from any cause in excess of Grade 1 (except focal neuropathy such as brachial plexopathy or carpal tunnel syndrome).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Major surgery",
        "text": "Major surgery within 3 weeks of randomization.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Allergic reactions",
        "text": "Known history of allergic reaction to cremophor/paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drugs.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Uncontrolled conditions",
        "text": "Clinically significant uncontrolled condition(s) including, but not limited to: Active infection; Symptomatic congestive heart failure; Unstable angina pectoris or cardiac arrhythmia; Myocardial infarction within last 6 months; Known active hepatitis B or hepatitis C with abnormal liver function tests or organ dysfunction; Uncontrolled hypertension; Psychiatric illness/social situations that would limit compliance; Any medical condition that, in the opinion of the investigator, places the subject at an unacceptably high risk.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Other cancers",
        "text": "A previous or concurrent cancer that is distinct in primary site or histology from breast cancer, except cervical carcinoma in situ, non-melanoma carcinoma of the skin, or in situ carcinoma of the bladder or another in situ cancer that is considered cured by the Investigator. Any cancer curatively treated more than 3 years prior to entry is permitted.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Pregnancy/Breastfeeding",
        "text": "Pregnant or breastfeeding.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedMinimumAge": "P18Y",
      "plannedSex": [
        {
          "code": "Male",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Male"
        },
        {
          "code": "Female",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Female"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}